Tags

Type your tag names separated by a space and hit enter

Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
Cancer. 2005 Oct 15; 104(8):1668-77.C

Abstract

BACKGROUND

Vascular endothelial growth factor-C (VEGF-C) plays an important role in lymphangiogenesis and activates VEGF receptor-3 (VEGFR-3). Lymphatic spread is an important prognostic factor in patients with lung adenocarcinoma. The aim of the current study was to determine whether the expression of VEGF-C and VEGFR-3 correlates with clinicopathologic factors and prognosis in patients with TNM classification T1 lung adenocarcinoma.

METHODS

The authors conducted a retrospective review of 129 consecutive patients who underwent complete resection for T1 lung adenocarcinoma. Immunohistochemical staining for VEGF-C, VEGF, VEGFR-3, CD34 (microvessels), tryptase (mast cells), and CD68 (macrophages) was performed to statistically analyze clinicopathologic implications of VEGF-C and VEGFR-3 status.

RESULTS

Of 129 patients with T1 lung adenocarcinoma, 56 (43.3%) patients were positive for tumor-cell VEGF-C and 73 (56.6%) and 69 (53.5%) patients were positive for tumor-cell and endothelial-cell VEGFR-3, respectively. Patients with positive staining for tumor-cell VEGF-C showed significantly less favorable survival rates than patients with negative staining (P = 0.031). The survival rates of patients with positive staining for tumor-cell and endothelial-cell VEGFR-3 were significantly lower than those with negative staining (P = 0.0034 and P = 0.0020, respectively). Patients with positive staining for both tumor-cell VEGF-C and endothelial-cell VEGFR-3 exhibited the most unfavorable prognoses. Multivariate analysis demonstrated that coexpression of tumor-cell VEGF-C and endothelial-cell VEGFR-3 was an independent negative prognostic factor (P = 0.0129) as well as N factor (P = 0.0020).

CONCLUSIONS

VEGF-C and VEGFR-3 status may be indicative of survival rates for patients with T1 lung adenocarcinoma.

Authors+Show Affiliations

Kojima H
Department of Respiratory Medicine, Obihiro Kyokai Hospital, Obihiro, Japan.
Shijubo N
No affiliation info available
Yamada G
No affiliation info available
Ichimiya S
No affiliation info available
Abe S
No affiliation info available
Satoh M
No affiliation info available
Sato N
No affiliation info available

MeSH

AdenocarcinomaAdultAgedAntigens, CD34Carcinoma, Non-Small-Cell LungEndothelium, VascularFemaleHumansImmunoenzyme TechniquesLung NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisSerine EndopeptidasesSurvival RateTryptasesVascular Endothelial Growth Factor AVascular Endothelial Growth Factor CVascular Endothelial Growth Factor Receptor-3

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16116610

Citation

Kojima, Hiroshi, et al. "Clinical Significance of Vascular Endothelial Growth factor-C and Vascular Endothelial Growth Factor Receptor 3 in Patients With T1 Lung Adenocarcinoma." Cancer, vol. 104, no. 8, 2005, pp. 1668-77.
Kojima H, Shijubo N, Yamada G, et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer. 2005;104(8):1668-77.
Kojima, H., Shijubo, N., Yamada, G., Ichimiya, S., Abe, S., Satoh, M., & Sato, N. (2005). Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer, 104(8), 1668-77.
Kojima H, et al. Clinical Significance of Vascular Endothelial Growth factor-C and Vascular Endothelial Growth Factor Receptor 3 in Patients With T1 Lung Adenocarcinoma. Cancer. 2005 Oct 15;104(8):1668-77. PubMed PMID: 16116610.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. AU - Kojima,Hiroshi, AU - Shijubo,Noriharu, AU - Yamada,Gen, AU - Ichimiya,Shingo, AU - Abe,Shosaku, AU - Satoh,Masaaki, AU - Sato,Noriyuki, PY - 2005/8/24/pubmed PY - 2006/1/13/medline PY - 2005/8/24/entrez SP - 1668 EP - 77 JF - Cancer JO - Cancer VL - 104 IS - 8 N2 - BACKGROUND: Vascular endothelial growth factor-C (VEGF-C) plays an important role in lymphangiogenesis and activates VEGF receptor-3 (VEGFR-3). Lymphatic spread is an important prognostic factor in patients with lung adenocarcinoma. The aim of the current study was to determine whether the expression of VEGF-C and VEGFR-3 correlates with clinicopathologic factors and prognosis in patients with TNM classification T1 lung adenocarcinoma. METHODS: The authors conducted a retrospective review of 129 consecutive patients who underwent complete resection for T1 lung adenocarcinoma. Immunohistochemical staining for VEGF-C, VEGF, VEGFR-3, CD34 (microvessels), tryptase (mast cells), and CD68 (macrophages) was performed to statistically analyze clinicopathologic implications of VEGF-C and VEGFR-3 status. RESULTS: Of 129 patients with T1 lung adenocarcinoma, 56 (43.3%) patients were positive for tumor-cell VEGF-C and 73 (56.6%) and 69 (53.5%) patients were positive for tumor-cell and endothelial-cell VEGFR-3, respectively. Patients with positive staining for tumor-cell VEGF-C showed significantly less favorable survival rates than patients with negative staining (P = 0.031). The survival rates of patients with positive staining for tumor-cell and endothelial-cell VEGFR-3 were significantly lower than those with negative staining (P = 0.0034 and P = 0.0020, respectively). Patients with positive staining for both tumor-cell VEGF-C and endothelial-cell VEGFR-3 exhibited the most unfavorable prognoses. Multivariate analysis demonstrated that coexpression of tumor-cell VEGF-C and endothelial-cell VEGFR-3 was an independent negative prognostic factor (P = 0.0129) as well as N factor (P = 0.0020). CONCLUSIONS: VEGF-C and VEGFR-3 status may be indicative of survival rates for patients with T1 lung adenocarcinoma. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/16116610/Clinical_significance_of_vascular_endothelial_growth_factor_C_and_vascular_endothelial_growth_factor_receptor_3_in_patients_with_T1_lung_adenocarcinoma_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓22]

Related Citations

More